(IN BRIEF) Sanofi has secured regulatory approval in China for two innovative medicines, Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome. The approvals expand treatment options for patients with serious cardiovascular and rare metabolic diseases and underscore … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged aficamten, cardiovascular disease, China NMPA, clinical phase 3 trials, familial chylomicronemia syndrome, FCS, Greater China, innovative medicines, Myqorzo, obstructive hypertrophic cardiomyopathy, oHCM, Olivier Charmeil, plozasiran, rare diseases, Redemplo, Sanofi, Sanofi Strengthens China Portfolio with Approval of Two Innovative Therapies for oHCM and FCS, siRNA therapy
(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release
Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (PRESS RELEASE) PARIS, 8-Sep-2021 — /EuropaWire/ — Sanofi … Read the full press release
Posted in France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, anti-human thymocyte antibody preparation, anti-thymocyte globulin, belumosudil, biopharmaceutical company, cGVHD, chronic graft-versus-host disease, fibrotic diseases, General Medicines, Harlan Waksal M.D., hematopoietic stem cell mobilizer, immuno-oncology therapies, immunomodulating agent, immunosuppressive, Kadmon Holdings, Mozobil®, Olivier Charmeil, plerixafor, polyclonal, Rezurock™, Sanofi, systemic therapy, Thymoglobulin®, transformative therapies, transplant portfolio
The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea Lyon, France, 15-10-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi, announced today the start of a phase III clinical trial in India … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged Olivier Charmeil, Rotavirus vaccine, Sanofi Pasteur, Shantha Biotechnics
Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?